Jarred J Iacovelli, Jeremy K Alpenglow, Stephen M Ratchford, Jesse C Craig, Jonah M Simmons, Jia Zhao, Van Reese, Kanokwan Bunsawat, Christy L Ma, John J Ryan, D Walter Wray
Heart failure with preserved ejection fraction (HFpEF) is characterized by impaired vascular endothelial function that may be improved by hydroxy-methylglutaryl-CoA (HMG-CoA) reductase enzyme inhibition. Thus, using a parallel, double-blind, placebo-controlled design, this study evaluated the efficacy of 30-day atorvastatin administration (10mg QD) on peripheral vascular function and biomarkers of inflammation and oxidative stress in sixteen patients with HFpEF (Statin: n=8, 74±6 yr, EF 52-73%; Placebo: n=8, 67±9 yr, EF 56-72%)...
February 22, 2024: Journal of Applied Physiology